167834-66-4

Upstream product

• 167837-47-0 N-(3-((tert-butyldiphenylsilyloxy)methyl)-2,4-dichlorophenyl)-2-(1,3-dioxoisoindolin-2-yl)-N-methylacetamide 
• 167837-46-9 N-(3-((tert-butyldiphenylsilyloxy)methyl)-2,4-dichlorophenyl)-2-(1,3-dioxoisoindol-in-2-yl)-acetamide 
• 167837-49-2 2,6-dichloro-1-methylsulfonyloxymethyl-3-[N-methyl-N-(phthalimidoacetyl)amino]benzene 
• 167837-44-7 tert-butyl(2,6-dichloro-3-nitrobenzyloxy)diphenylsilane 
• 167837-48-1 N-(2,4-dichloro-3-(hydroxymethyl)phenyl)-2-(1,3-dioxoisoindolin-2-yl)-N-methylacetamide 
• 167837-45-8 3-amino-1-(tert-butyldiphenylsilyloxymethyl)-2,6-dichlorobenzene 
• 160647-01-8 2,6-Dichloro-3-nitrobenzyl alcohol 
• 167834-62-0 N-[2,4-Dichloro-3-(2-methyl-quinolin-8-yloxymethyl)-phenyl]-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetamide 
• 167834-56-2 8-(2,6-Dichloro-3-nitro-benzyloxy)-2-methyl-quinoline 
• 179625-53-7 8-(2,6-dichloro-3-aminobenzyloxy)-2-methylquinoline 
• 29682-46-0 2,6-dichloro-3-nitrotoluene 
• 167834-64-2 8-[2,6-dichloro-3-[N-(phthalimidoacetyl)-N-methylamino]benzyloxy]-2-methylquinoline 

Downstream Products

• 179621-04-6 8-[2,6-Dichloro-3-[N-[4-(methoxycarbonyl)cinnamoylglycyl]-N-methylamino]benzyloxy]-2-methylquinoline 
• 167838-69-9 8-[3-[N-[(E)-3-(6-Carboxypyridin-3-yl)acryloylglycyl]-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline 
• 179621-23-9 8-[3-[N-(4-carboxycinnamoylglycyl)-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline 
• 215238-33-8 8-[3-[N-(3-Carboxycinnamoylglycyl)-N-methylamino]-2,6-dichlorobenzyloxy]-2-methylquinoline 

Relevant academic research and scientific papers

Novel series of O-substituted 8-quinolines and 4-benzothiazoles as potent antagonists of the bradykinin B2 receptors

The synthesis and the SAR study of novel O-substituted 8-quinolines and 4-benzothiazoles as highly potent non-peptide bradykinin B2 receptor antagonists are described. Several members of this series of antagonists efficiently inhibited the BK-induced vasoconstriction on different isolated organ preparations.

A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a]pyridine moiety

Recently we reported on overcoming the species difference of our first orally active non-peptide bradykinin (BK) B2 receptor antagonists, incorporating an 8-[[3-(N-acylglycyl-N-methylamino)-2,6-dichlorobenzyl]oxy]- 3-halo-2-methylimidazo[1,2-α]